The U.S. Food and Drug Administration has its hands full making sure medical AI products are safe, efficacious and trustworthy before they hit the market. The rise of ever-more-innovative iterations of the technology—not least generative AI—is only adding to the burden. 

Among AI’s most watchful stakeholders are healthcare organizations in need of AI talent and AI talent in need of work in healthcare. Both groups need to keep up with the technology in its present as well as future iterations.

Some 60% of IT professionals and 51% of operational leaders admit they’re reluctant to involve clinicians in software decisions. 

As 2024 winds down and the number of FDA-approved medical devices packing AI approaches 1,000—the agency had the tally at 950 as of August—the industry finds itself at a “critical inflection point.” 

Nurses tend to feel optimistic if not exactly excited about AI’s advances into their profession. Those who hold back tend to share a common concern—sacrificing care quality for the sake of tech-enabled efficiency. 

Generative AI is fixing to transform the pharmaceutical industry. However, not all adopters will reap rewards in comparable degrees.  

10 notable quotes about AI from the past 5 days.

In the rush to do something, anything with AI, are America’s business leaders playing fast and loose with the risks?